Managing the Overlapping Toxicities of Cabozantinib plus Nivolumab, a New Standard of Care in Kidney Cancer - Beyond the Abstract

Significant progress has been made in recent years in the systemic therapy of advanced renal cell carcinoma (RCC), with now 3 combinations of immuno-oncologic (IO) agents with tyrosine kinase inhibitors (TKI) and a double IO option proven to improve survival compared to sunitinib in the first-line setting (see Table 1). These regimens are nivolumab/ipilimumab, pembrolizumab/axitinib, pembrolizumab/lenvatinib, avelumab/axitinib, and cabozantinib/nivolumab. These regimens have become the new standard of care; however, they have not been directly compared against each other in clinical trials, hence the choice of one over another is not currently clear.


Table 1: Phase 3 trials of new combination regimens versus sunitinib
BTA_Apolo.png

N = number, ORR = objective response rate, mPFS = median progression-free survival, mOS = median overall survival, HR = hazard ratio, CI = confidence interval, OR = odds ratio, RR = relative risk

AE management for IO/TKI combination regimens can be particularly challenging. Due to overlapping toxicities, it may be unclear which agent is the culprit; hence, deciding on which agent to hold or dose reduce is not straightforward. Furthermore, decisions must be made on whether to initiate systemic corticosteroids or other immunosuppressive therapy, which may counteract the beneficial effects of the IO component.9

The recent review article by McGregor et al.9  is a much-needed analysis and summary of the adverse event (AE) data of CaboNivo in clinical trials and provides practical management principles for this IO/TKI combination. Here, we highlight some of the data presented in the article, especially the common overlapping toxicities between IO and TKI (Figure 1) and some features which may attribute them to one agent over the other, along with management principles. One of the valuable points in the review is to take a multidisciplinary approach to these AEs to ensure optimal AE management.
BTA_Apolo2.png
Figure 1: Adverse events of cabozantinib and nivolumab9

Diarrhea: Cabozantinib-associated diarrhea typically occurs early (within the first few weeks), has a gradual onset, and is associated with small, frequent stools, bloating, and flatulence. It generally resolves within a week with antidiarrheal agents and/or dose interruption.10,11 On the other hand, nivolumab can cause diarrhea and colitis. Colitis can present as a sudden onset of large-volume watery stools and is associated with abdominal cramping. It may persist despite antidiarrheal medications and holding the agent.12

If the history is unclear on which agent may be causative, and the diarrhea is grade ≥2, both agents should be held and a workup performed to rule out infectious causes such as Clostridium difficile and parasites. Gastroenterology should also be consulted to perform an endoscopic workup for colitis. If diarrhea rapidly improves after withholding both agents (within a week), cabozantinib is likely the offending agent; however, if it persists, nivolumab is the more likely culprit.9

Rash: Both agents are commonly associated with dermatologic toxicity, which, although rarely life-threatening can be very distressing. Cabozantinib can cause palmar-plantar erythrodysesthesia (PPE) which usually requires supportive management but will occasionally require dose interruptions and/or reductions.13,14 Cabozantinib may also cause a number of other rashes, most of which can be managed supportively. Nivolumab can cause immune-related rashes, pruritus, and vitiligo. Grade 1 and 2 rashes can be treated with topical corticosteroids, whereas grade ≥ 3 rashes will require systemic corticosteroids.15-17 Rare and serious skin toxicities such as Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug rash with eosinophilia and systemic symptoms would require systemic immunosuppressive therapy and permanent discontinuation of nivolumab.9,18,19 


Hepatic: 
Both agents can induce AST and ALT elevations via different mechanisms.20,21 For grade ≥ 2 elevations in AST or ALT, both agents should be withheld until improvement to grade ≤ 1, and corticosteroids may be considered depending on the duration of the AE.14,18 If upon withholding both agents, the AST and ALT elevations improve without specific intervention, the likely culprit is cabozantinib, and it should be restarted at a lower dose. However, if the AST/ALT elevations persist beyond 2 weeks of holding both agents, the AE is likely related to nivolumab, and it should either be withheld or discontinued, depending on severity, and immunosuppressive therapy initiated. For severe hepatic dysfunction (ALT/AST ≥ 10x ULN or ≥ 3x ULN with bilirubin ≥ 2x ULN), both cabozantinib and nivolumab should be permanently discontinued.9


Renal: 
Although both agents can cause nephrotoxicity, there are differences in the clinical manifestation. Cabozantinib can cause proteinuria through VEGF inhibition.22 Hence, urine protein should be monitored every 1-2 months during treatment with a urine protein: creatinine ratio (UPCR). UPCR ≥ 3.5 requires withholding cabozantinib until it goes below 3.5, at which point cabozantinib may be restarted at a lower dose. If despite withholding cabozantinib, the UPCR remains ≥ 3.5 and there is no nephrotic syndrome, cabozantinib can be restarted at a lower dose based on the assessment of risks vs benefits. However, in the presence of nephrotic syndrome, cabozantinib should not be restarted.9 Nivolumab can cause an immune-related nephrotic syndrome, typically characterized by hematuria, oliguria, raised creatinine, and urine sediments. This may require a renal biopsy to confirm the diagnosis, after which commencement of immunosuppressive therapy with consultation of a nephrologist would be indicated.18,23,24

Endocrinopathies: The commonest endocrinopathies associated with both agents are hypo- and hyperthyroidism, as well as adrenal insufficiency. It is often difficult to identify the responsible agent; however, this would not influence the management of endocrinopathy. TSH and cortisol levels should be monitored during therapy. Hypothyroidism can be treated with synthetic thyroid hormones using established guidelines. Hyperthyroidism is usually transient before “burning out” to hypothyroidism. It is managed with beta-blockers and, less frequently, methimazole if symptomatic.25,26 With both agents, adrenal insufficiency can be primary and secondary. This should be treated with hormone replacement as indicated.18,27,28

Although guidelines recommend interrupting therapy for endocrinopathies, the review pragmatically recommends continuing therapy while supportively managing endocrine AEs.9

Conclusion: Proper AE management is key to maximizing the benefit of CaboNivo in metastatic RCC. This involves a multidisciplinary approach to definitively diagnose the AE, identify the responsible agent, and implement effective management, whether by withholding the agent(s), dose reduction of cabozantinib, immunosuppressive therapy, or a combination of these strategies.

Written by: Elias A. Chandran, MBBS, FRACP, and Andrea B. Apolo, MD, National Cancer Institute, Bethesda, MD

References:

  1. Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277-90.
  2. Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barthélémy P, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020;5(6):e001079-e.
  3. Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116-27.
  4. Rini BI, Plimack ER, Stus V, Waddell T, Gafanov R, Pouliot F, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426. Journal of Clinical Oncology. 2021;39(15_suppl):4500-.
  5. Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103-15.
  6. Choueiri TK, Motzer RJ, Rini BI, Haanen J, Campbell MT, Venugopal B, et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2020;31(8):1030-9.
  7. Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829-41.
  8. Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289-300.
  9. McGregor B, Mortazavi A, Cordes L, Salabao C, Vandlik S, Apolo AB. Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review. Cancer Treatment Reviews. 2022;103:102333.
  10. Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1814-23.
  11. Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol. 2017;35(6):591-7.
  12. Apolo AB, Nadal R, Girardi DM, Niglio SA, Ley L, Cordes LM, et al. Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. Journal of Clinical Oncology. 2020;38(31):3672-84.
  13. Zuo RC, Apolo AB, DiGiovanna JJ, Parnes HL, Keen CM, Nanda S, et al. Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib. JAMA Dermatol. 2015;151(2):170-7.
  14. Exelixis, Inc. Cabometyx (cabozantinib) [package insert]. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208692s010lbl.pdf. Revised January 2021. Accessed January 27, 2021.
  15. Shen J, Chang J, Mendenhall M, Cherry G, Goldman JW, Kulkarni RP. Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management. Ther Adv Med Oncol. 2018;10:1758834017751634.
  16. Shi VJ, Rodic N, Gettinger S, Leventhal JS, Neckman JP, Girardi M, et al. Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol. 2016;152(10):1128-36.
  17. Belum VR, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer. 2016;60:12-25.
  18. Bristol-Myers Squibb Company. Opdivo (nivolumab) [package insert]. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125554s090lbl.pdf. Revised January 2021. Accessed January 27, 2021.
  19. Bristol-Myers Squibb. Opdivo treatment modifications. https://www.opdivohcp.com/dosing/treatment-modifications. Updated December 2020. Accessed January 18, 2021.
  20. National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: clinical and research information on drug-induced liver injury. https://www.ncbi.nlm.nih.gov/books/NBK548279/. Revised January 4, 2017. Accessed April 12, 2021.
  21. Grover S, Rahma OE, Hashemi N, Lim RM. Gastrointestinal and hepatic toxicities of checkpoint inhibitors: algorithms for management. Am Soc Clin Oncol Educ Book. 2018;38:13-9.
  22. Cappagli V, Moriconi D, Bonadio AG, Giannese D, La Manna G, Egidi MF, et al. Proteinuria is a late-onset adverse event in patients treated with cabozantinib. J Endocrinol Invest. 2021;44(1):95-103.
  23. Mayo Clinic. Glomerulonephritis. https://www.mayoclinic.org/diseases-conditions/glomerulonephritis/diagnosis-treatment/drc-20355710#:~:text=Glomerulonephritis%20often%20comes%20to%20light,possible%20damage%20to%20the%20glomeruli. Published February 6, 2020. Accessed February 12, 2021.
  24. Cleveland Clinic. Glomerulonephritis (GN). https://my.clevelandclinic.org/health/diseases/16167-glomerulonephritis-gn. Updated November 4, 2020. Accessed June 8, 2021.
  25. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343-421.
  26. Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670-751.
  27. Lodish MB. Clinical review: kinase inhibitors: adverse effects related to the endocrine system. J Clin Endocrinol Metab. 2013;98(4):1333-42.
  28. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158-68.

Read the Abstract
email news signup